Opus Genetics (IRD) Short term Debt (2021 - 2022)
Opus Genetics' (IRD) quarterly Short term Debt came in at $215000.0 in Q1 2022, down 60.04% on a QoQ basis from $538000.0 in Q4 2021.
Opus Genetics (IRD) Short term Debt (2021 - 2022) Analysis & Trends
Opus Genetics (IRD) has 2 years of Short term Debt data on file, last reported at $215000.0 in Q1 2022.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $215000.0 in Q1 2022; TTM through Mar 2022 was $215000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $538000.0, changed N/A from the prior year.
- Short term Debt for Q1 2022 stood at $215000.0, down from $538000.0 in the prior quarter.
- Over the last five years, Short term Debt for IRD reached as high as $538000.0 in Q4 2021 and fell as low as $215000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Opus Genetics | 3.27 Mn | -56.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 215,000.00 |
| Dec 31, 2021 | 538,000.00 |